Treatments for skin conditions

Abstract

Compositions and methods for treating skin lesions using topically administered JAK/STAT inhibitors for treating skin lesions and disease such as bullous pemphigoid, bullous impetigo, bullous lichen planus, lichen planus of the mucosa, and the like.

1 . A method for treating skin conditions, comprising topically administering to a subject in need of treatment a composition comprising up to about 5% (w/w) of a JAK/STAT inhibitor and a base. 
     
     
         2 . The method of  claim 1 , wherein the composition is in the form of a lotion, foam, liniment, balm, soap, shampoo, suppository and the like and combinations thereof. 
     
     
         3 . The method of  claim 1 , wherein the JAK/STAT inhibitor is selected from the group consisting of ruxolitinib (INCB 018424), tofacitinib (CP690550), AG490, momelotinib (CYT387), partcitinib (SB 1518), baricitinib (LY3009104), fedratinib (TG101348), BMS-911543, lestaurtinib (CEP- 701), fludarabine, epigallocatechin-3-gallate (EGCG), baricitinib, momelotinib, pacritinib, peficitinib, ABT 494, AT 9283, decernmotinib, filgotinib, gandotinib, INCB 39110, PF 4965842, R348, AZD 1480, BMS 911543, cerdulatinib, INCB 052793, NS 018, C 410, CT 1578, JTE 052, PF 6263276, R 548, TG 02, lumbricus rebellus extract, ARN 4079, AR 13154, UR 67767, CS510, VR588, DNX 04042, hyperforin, and pharmaceutically acceptable salts and combinations thereof. 
     
     
         4 . The method of  claim 1 , wherein JAK/STAT inhibitor is tofacitinib. 
     
     
         5 . The method of  claim 1 , wherein the base is selected from the group consisting of white petrolatum, white petrolatum USP, mineral jelly, petroleum jelly, yellow petrolatum, yellow soft paraffin, white soft paraffin, fats, waxes, sterols, fat-soluble vitamins, monoglycerides, diglycerides, triglycerides, phospholipids, PCCA plasticized base, versabase, and combinations thereof. 
     
     
         6 . The method of  claim 1 , wherein the base has a concentration of about 45% (w/w) to about 99.75% (w/w) of the total composition. 
     
     
         7 . The method of  claim 1 , wherein the skin condition is selected from the group consisting of Epidermolysis bullosa simplex, congenital aplasia cutis, neonatal pemphigus, neonatal herpes gestationis, staphylococcal scalded skin syndrome, incontinentia pigmenti, epidermolytic ichthyosis, linear IgA dermatosis, bullous pemphigoid, bullous impetigo, bullous lichen planus, lichen planus of the mucosa, tuberous sclerosis-associated angiofibromas, angiofibromas, trichoepitheliomas, skin lesions associated with Birt-Hogg-Dube syndrome, of the skin of the face, skin lesions associated with Langerhans Cell Histiocytosis, Vascular malformations and tumors, Port Wine Stains, Kaposi sarcoma, Epidermal nevi, treatment-resistant hemangiomas, sensitive skin, fragile skin, or combinations thereof. 
     
     
         8 . The method of  claim 1 , wherein the composition further comprises a solvent, antioxidant, emulsifying agent, humectant, analgesic agent, topical debriding agent, topical emollient, and the like and combinations thereof. 
     
     
         9 . The method of  claim 1 , wherein the composition further comprises a solvent. 
     
     
         10 . The method of  claim 11 , wherein the solvent is selected from the group consisting of isopropyl alcohol, benzyl alcohol, dipropylene glycol methyl-ether, butylated hydroxytoluene dipropylene glycol monomethyl-ether, 1-methoxy 2-propanol (glysolv PM/lcinol PM), Ethylene glycol monobutylether (butyl glyxolv/butyl icinol), Butyl di glysolv (butyl-icinol), Transcutol, propylene glycol (PG), N-methyl-2 pyrrolidone (NMP), methylene chloride, diethyl ether, ethanol, acetonitrile, ethyl acetate, ethylene glycol, propylene glycol, dimethyl polysiloxane (DMPX), oleic acid, caprylic acid, 1-octanol, ethanol (denatured or anhydrous), and combinations thereof. 
     
     
         11 . The method of  claim 11 , wherein the solvent has a concentration of about 5.0% (w/w) to about 15.0% (w/w). 
     
     
         12 . The method of  claim 1 , wherein the composition further comprises an antioxidant selected from the group consisting of butylated hydroxytoluene, ascorbic acid, ascorbic palmitate, butylated hydroxyanisole, 2,4,5-trihydroxybutyrophenone, 4-hydroxymethyl-2,6-di-tert-butylphenol, erythorbic acid, gum guaiac, propyl gallate, thiodipropionic acid, dilauryl thiodipropionate, tert-butylhydroquinone, tocopherol, and pharmaceutically acceptable salt and ester thereof, and combinations thereof. 
     
     
         13 . The method of claim  14 , wherein the antioxidant has a concentration of about 0.01% (w/w) to about 1% (w/w).